BioNTech (NASDAQ:BNTX) Shares Up 4.4% – Should You Buy?

BioNTech SE (NASDAQ:BNTX)’s stock price rose 4.4% during trading on Friday . The stock traded as high as $125.40 and last traded at $124.08. Approximately 419,270 shares were traded during trading, a decline of 48% from the average daily volume of 809,889 shares. The stock had previously closed at $118.84.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BNTX. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and boosted their target price for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. HSBC boosted their price objective on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and set a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. Finally, Berenberg Bank started coverage on BioNTech in a research report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price objective on the stock. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $138.67.

BioNTech Price Performance

The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $113.84 and a two-hundred day moving average of $99.36. The firm has a market cap of $29.34 billion, a P/E ratio of -59.09 and a beta of 0.22.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.73 EPS. Sell-side analysts expect that BioNTech SE will post -3.72 EPS for the current year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds have recently modified their holdings of BNTX. Baillie Gifford & Co. boosted its position in shares of BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after purchasing an additional 31,773 shares during the period. FMR LLC lifted its stake in BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after buying an additional 5,598,190 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its holdings in shares of BioNTech by 4.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after buying an additional 24,426 shares during the period. Candriam S.C.A. increased its position in shares of BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after acquiring an additional 418,695 shares in the last quarter. Finally, Fred Alger Management LLC acquired a new stake in shares of BioNTech during the third quarter valued at approximately $59,485,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.